Tag
HPV-positive keratinizing nasopharyngeal carcinoma demonstrates significantly improved overall survival compared to HPV-negative cases, underscoring the prognostic and clinical relevance of HPV testing in NPC management.
This study highlights how HPV and TP53 molecular subtyping in stage I vulvar squamous cell carcinoma delineates survival outcomes and recurrence risks, supporting its role in personalized management strategies.
Solid organ transplant recipients have increased risk of HPV-driven anal dysplasia and cancer due to unique immune alterations from immunosuppression. This article explores the transplant-specific immune dysfunction underlying persistent HP
Solid organ transplant recipients exhibit heightened risk for HPV-associated anal dysplasia and cancer due to unique immunosuppressive alterations. A transplant-tailored model of mucosal immune dysfunction elucidates mechanisms driving pers
FAM19A4, SOX1, and PAX1 methylation assays demonstrate high diagnostic accuracy for identifying CIN3+ among non-16/18 hrHPV-positive women, outperforming cytology and reducing unnecessary colposcopies.
This study examines how pre-existing immunocompromise affects survival and outcomes in patients with HPV-positive oropharyngeal cancer treated surgically. Immunocompromised patients showed significantly worse overall survival compared to no
Introduction and Context Despite being highly preventable, cervical cancer remains a significant health threat. The...
This report examines a clinical trial using 30-minute daily saturated saline immersion to treat refractory plantar warts, achieving an 88.2% complete remission rate without pain or recurrence.
In a multi-center cohort of 345 surgically treated patients aged 70 or older with tonsil or base‑of‑tongue SCC, p16 positivity was associated with substantially better 5‑year overall and disease‑free survival compared with p16‑negative tumo
In a retrospective cohort of 158 HPV-positive tonsil SCC patients, omission of prophylactic contralateral tonsillectomy during TORS was not associated with worse survival and showed trends toward fewer hemorrhages, ED visits, and shorter ho
This study assesses the feasibility and performance of using self-collected urine and vaginal samples with the BD Onclarity® HPV assay for cervical cancer screening in Japanese women with abnormal cytology, highlighting concordance and sens
A comprehensive 2025 systematic review informing the Canadian Task Force finds cytology remains effective into the 60s, HPV-based strategies detect more precursors but increase colposcopy and false positives, and self-sampling improves upta
A Finnish longitudinal study reveals that elevated Epstein-Barr virus antibody levels are significantly associated with persistent oral HPV infections, highlighting potential viral interplay in oropharyngeal oncogenesis risk.
This study explores how early Epstein-Barr virus (EBV) infection and immune responses influence oral human papillomavirus (HPV) infections in children, revealing the interplay between EBV serology, paternal education, and oral HPV acquisiti
HPV-related oropharyngeal cancer incidence has surpassed cervical cancer, with men facing a 5-10 fold higher risk. Understanding this shift, symptoms, risks, and the critical role of HPV vaccination can transform prevention and early detect
Many common disorders are actually precancerous. Learn the stages of cancer development, six precancerous conditions to watch, their risk factors, tests, and practical prevention and management steps.
The E3311 phase II trial shows excellent long-term survival with deintensified postoperative management after transoral surgery in HPV-associated oropharyngeal cancer, with most patients spared from high-dose radiation and chemotherapy.
Emerging research reveals heightened risk of cervical cancer in women aged 65 and older, driven by human papillomavirus (HPV). Continued screening is crucial to address increasing incidence and improve outcomes.
Recent research suggests that a 2-dose HPV vaccine regimen offers similar long-term protection against HPV-16 and HPV-18 as the 2+1-dose regimen, challenging the necessity of booster doses.
This article explores the common misconceptions and scientific facts about HPV infections, offering insights on prevention and management.